REYAGEN study. Optimization of unboosted atazanavir dosing, when associated with tenofovir, guided by pharmacogenetics profile of HIV-patients
Phase of Trial: Phase IV
Latest Information Update: 14 Jul 2015
At a glance
- Drugs Atazanavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Pharmacogenomic; Pharmacokinetics
- Acronyms REYAGEN
- 06 Mar 2013 Primary endpoint 'Trough-drug-concentration' has been met.
- 06 Mar 2013 Status changed from recruiting to completed.
- 06 Mar 2013 Results presented at the 20th Conference on Retroviruses and Opportunistic Infections.